Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€4.89

€4.89

2.800%
0.131
2.800%
€8.59

€8.59

 
06.02.26 / Tradegate WKN: A2DMZL / Symbol: MNKD / Name: MannKind / Stock / Biotechnology & Medical Research / Small Cap /
Latest predictions
€9.27
26.01.26
4.80%
buy
08.01.26
-6.78%
buy
05.12.25
-4.55%
buy
24.11.25
9.80%
buy
€6.04
13.11.25
9.27%
buy
€6.49
11.11.25
2.29%
buy
Best running prediction
€6.00
07.08.25
65.34%
buy
Your prediction

MannKind Corp. Stock

There is an upward development for MannKind Corp. compared to yesterday, with an increase of €0.13 (2.800%).
With 24 Buy predictions and not a single Sell prediction MannKind Corp. is an absolute favorite of our community.
With a target price of 8 € there is a hugely positive potential of 63.47% for MannKind Corp. compared to the current price of 4.89 €.
So far the community has only identified positive things for MannKind Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of MannKind Corp. in the next few years

Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of MannKind Corp. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
MannKind Corp. 2.800% 0.266% 1.852% -9.937% -0.770% 1.064% 25.584%
Evolus Inc -2.140% -7.576% -26.210% -71.181% -32.844% -57.442% -36.237%
Madrigal Pharmaceuticals inc. 1.980% -2.180% -15.435% 27.021% -18.997% 56.512% 304.934%
Heron Therapeutics Inc. 2.350% -5.009% 1.336% -38.542% -4.668% -64.997% -93.440%

Comments

Prediction Buy
Perf. (%) 4.80%
Target price 9.265
Change
Ends at 26.01.27

MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Ratings data for MNKD provided by MarketBeat
Show more

MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Ratings data for MNKD provided by MarketBeat
Show more

MannKind (NASDAQ:MNKD) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Ratings data for MNKD provided by MarketBeat
Show more

News

Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/1a599f395be31e2f508c3aa7decb988f9ce983b7-1401x1251.png?w=1401&h=1251
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?

On Dec. 17, 2025, Michael Castagna, Chief Executive Officer of MannKind Corporation (NASDAQ:MNKD), executed an exercise and immediate sale of 65,804 common shares for a transaction value of